Incidence and risk factors of hypothyroidism in psychiatric outpatients with long-term lithium treatment: a 10-year retrospective hospital-based study.

IF 3.6 3区 医学 Q1 PSYCHIATRY
Kanthee Anantapong, Chavisa Jittpratoom, Jarurin Pitanupong
{"title":"Incidence and risk factors of hypothyroidism in psychiatric outpatients with long-term lithium treatment: a 10-year retrospective hospital-based study.","authors":"Kanthee Anantapong, Chavisa Jittpratoom, Jarurin Pitanupong","doi":"10.1186/s12991-025-00578-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The study aimed to assess the incidence of lithium-induced hypothyroidism and its associated factors in psychiatric outpatients on long-term lithium therapy.</p><p><strong>Methods: </strong>A retrospective study at Songklanagarind Hospital (January 1, 2013, to September 30, 2022) focused on clinical (overt) and subclinical forms of lithium-induced hypothyroidism. Subclinical hypothyroidism, characterised by elevated thyroid stimulating hormone (TSH) but normal thyroxine (FT4) levels, and clinical hypothyroidism, by low FT4 and high TSH, were analysed. Patients with less than 3 months of lithium therapy or prior thyroid conditions were excluded. We used survival analysis and logistic regression to investigate incidence and factors.</p><p><strong>Results: </strong>Among 461 on lithium maintenance therapy, 279 outpatients met the inclusion criteria; however, only 166 (59%) were monitored for thyroid functions during the study period and included in the final analyses, mostly female (53.6%) with bipolar disorder (72.9%), median age 42.0 years. The median duration of maintenance therapy was 3.7 years (IQR = 1.0-9.3). Over a decade, 30 patients developed lithium-induced hypothyroidism, primarily subclinical (28 cases), at an incidence rate of 0.0212 cases per patient-year. Hypothyroidism manifested after 14.4 months of lithium therapy (IQR = 5.2-53.2), with a prominent decline of survival curve within the first year. Younger age (adjusted OR = 0.95, P = 0.001), presence of physical comorbidities (adjusted OR = 2.69, P = 0.039), and higher lithium levels (P = 0.003) were associated with hypothyroidism.</p><p><strong>Conclusions: </strong>Despite low incidence, regular thyroid monitoring is advised for patients on lithium. The study identifies risk factors for lithium-induced hypothyroidism, aiding in patient risk assessment and monitoring protocols.</p>","PeriodicalId":7942,"journal":{"name":"Annals of General Psychiatry","volume":"24 1","pages":"39"},"PeriodicalIF":3.6000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181824/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of General Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12991-025-00578-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The study aimed to assess the incidence of lithium-induced hypothyroidism and its associated factors in psychiatric outpatients on long-term lithium therapy.

Methods: A retrospective study at Songklanagarind Hospital (January 1, 2013, to September 30, 2022) focused on clinical (overt) and subclinical forms of lithium-induced hypothyroidism. Subclinical hypothyroidism, characterised by elevated thyroid stimulating hormone (TSH) but normal thyroxine (FT4) levels, and clinical hypothyroidism, by low FT4 and high TSH, were analysed. Patients with less than 3 months of lithium therapy or prior thyroid conditions were excluded. We used survival analysis and logistic regression to investigate incidence and factors.

Results: Among 461 on lithium maintenance therapy, 279 outpatients met the inclusion criteria; however, only 166 (59%) were monitored for thyroid functions during the study period and included in the final analyses, mostly female (53.6%) with bipolar disorder (72.9%), median age 42.0 years. The median duration of maintenance therapy was 3.7 years (IQR = 1.0-9.3). Over a decade, 30 patients developed lithium-induced hypothyroidism, primarily subclinical (28 cases), at an incidence rate of 0.0212 cases per patient-year. Hypothyroidism manifested after 14.4 months of lithium therapy (IQR = 5.2-53.2), with a prominent decline of survival curve within the first year. Younger age (adjusted OR = 0.95, P = 0.001), presence of physical comorbidities (adjusted OR = 2.69, P = 0.039), and higher lithium levels (P = 0.003) were associated with hypothyroidism.

Conclusions: Despite low incidence, regular thyroid monitoring is advised for patients on lithium. The study identifies risk factors for lithium-induced hypothyroidism, aiding in patient risk assessment and monitoring protocols.

长期锂治疗的精神科门诊患者甲状腺功能减退的发病率和危险因素:一项10年回顾性医院研究
背景:本研究旨在评估长期锂治疗的精神科门诊患者锂致甲状腺功能减退的发生率及其相关因素。方法:在Songklanagarind医院(2013年1月1日至2022年9月30日)进行回顾性研究,重点研究锂诱发的临床(显性)和亚临床形式的甲状腺功能减退症。亚临床甲状腺功能减退,特点是促甲状腺激素(TSH)升高,但甲状腺素(FT4)水平正常,临床甲状腺功能减退,低FT4和高TSH,进行了分析。锂治疗少于3个月或既往甲状腺疾病的患者被排除在外。我们采用生存分析和逻辑回归来调查发病率及其影响因素。结果:461例接受锂维持治疗的患者中,279例符合纳入标准;然而,在研究期间,只有166例(59%)患者进行了甲状腺功能监测,并纳入了最终分析,其中大多数为女性(53.6%),患有双相情感障碍(72.9%),中位年龄42.0岁。维持治疗的中位持续时间为3.7年(IQR = 1.0-9.3)。十年来,30例患者出现锂诱发的甲状腺功能减退,主要是亚临床(28例),发病率为0.0212例/患者年。锂治疗14.4个月后出现甲状腺功能减退(IQR = 5.2-53.2),第一年生存曲线下降明显。年龄较小(调整后的OR = 0.95, P = 0.001)、存在身体合并症(调整后的OR = 2.69, P = 0.039)和较高的锂水平(P = 0.003)与甲状腺功能减退有关。结论:尽管发病率很低,但建议对服用锂的患者进行定期甲状腺监测。该研究确定了锂诱发甲状腺功能减退的危险因素,有助于患者风险评估和监测方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.60
自引率
2.70%
发文量
43
审稿时长
>12 weeks
期刊介绍: Annals of General Psychiatry considers manuscripts on all aspects of psychiatry, including neuroscience and psychological medicine. Both basic and clinical neuroscience contributions are encouraged. Annals of General Psychiatry emphasizes a biopsychosocial approach to illness and health and strongly supports and follows the principles of evidence-based medicine. As an open access journal, Annals of General Psychiatry facilitates the worldwide distribution of high quality psychiatry and mental health research. The journal considers submissions on a wide range of topics including, but not limited to, psychopharmacology, forensic psychiatry, psychotic disorders, psychiatric genetics, and mood and anxiety disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信